Introduction Heptares Therapeutics Ltd., a company known for creating innovative medicines for G protein-coupled receptors, boasts a promising pipeline of unprecedented drug candidates. These novel therapeutics carry the potential to drastically shift the paradigm of treating severe diseases such as alzheimer's, parkinson's, schizophrenia. Established in 2007 by Richard Henderson and others, the company's headquarters is located in Welwyn Garden City, UK. |
Disease Domain | Count |
---|---|
Neoplasms | 2 |
Nervous System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Monoclonal antibody | 1 |
Target |
Mechanism EP4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CGRP receptor antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Oct 2024 |
Sponsor / Collaborator |
Start Date20 Feb 2024 |
Sponsor / Collaborator |
Start Date13 Jul 2023 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HTL-0039732 ( EP4 ) | Advanced Malignant Solid Neoplasm More | Phase 1/2 |
KY-1051 ( CXCR4 ) | Solid tumor More | Preclinical |
HTL-18318 ( M1 receptor ) | Alzheimer Disease More | Pending |
HTL-0014242 ( mGluR5 ) | Amyotrophic Lateral Sclerosis More | Pending |
AZD-4635 ( A2aR ) | Attention Deficit Disorder With Hyperactivity More | Pending |